Skip to content
    Font Size

    Test Pinpoints Aggressive Prostate Tumors

    Goal of New Test Is to Determine Which Men Will and Will Not Need Treatment for Prostate Cancer

    New Prostate Cancer Test Shows Promise continued...

    The federally funded study involved 71 men who were diagnosed as having small, low-grade, and low-stage prostate cancer based on their PSA results. At the time of their diagnosis, their blood had been banked.

    By an average of nearly four years later, 39 had unfavorable biopsy results that signaled a need for treatment.

    The PHI test was performed on blood samples from all 71 men.

    "When we combined the [biopsy results] and the serum Prostate Health Index, we were able to predict seven in 10 men that might progress," Veltri says.

    Veltri says the PHI test won't replace biopsies but will hopefully allow men to have them every other year instead of year.

    His lab is now conducting an expanded study to look for other biomarkers that may predict aggressive cancers.

    Test May Predict Prostate Cancer Spread

    Also at the meeting, researchers reported using a microchip to detect circulating tumor cells in the blood of people with prostate cancer.

    The presence of circulating tumor cells, or CTCs, in the blood is an indication of cancer spread, says Sunitha Nagrath, PhD, an instructor of surgery and bioengineering at Harvard Medical School.

    CTCs also carry molecular signatures that can be used to guide targeted drug therapy, she says. The problem: There are only a few CTCs in millions of cells, she tells WebMD. "It’s like looking for a needle in a haystack."

    The CTC-chip can capture about 200 circulating tumor cells from a teaspoon of blood, she says.

    In a small pilot study, the researchers found CTCs in nearly half of 20 people with early-stage prostate cancer and in two-thirds of people with advanced cancer.

    "We think that's an indicator they are more prone to metastasis (cancer spread), but that remains to be proven," Nagrath says.

    The test is not commercially available.

    "Eventually we hope that when a patient walks in, we can take a simple blood test that tells us if a cancer will spread and also about its molecular signature," she says.

    Massimo Cristofanilli, MD, chairman of the department of medical oncology at Fox Chase Cancer Center, is cautiously enthusiastic, saying that a lot more work is needed before either test can be integrated into patient care.

    Today on WebMD

    man with doctor
    Symptoms, risks, treatments
    man coughing
    Men shouldn’t ignore
    prostate cancer cells
    What does this diagnosis mean?
    doctor and male patient
    Is it worth it?
    cancer fighting foods
    15 Cancer Symptoms Men Ignore
    Prostate Enlarged
    Picture Of The Prostate
    Prostate Cancer Quiz
    screening tests for men
    Prostate Cancer Symptoms
    Vitamin D